Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Composition containing fibrate drug and taurine

A technology of phenoxyaromatic acids and compositions, applied in the field of pharmacy, can solve the problem of no blood lipids and the like

Active Publication Date: 2006-10-25
SHENZHEN AUSA PHARM CO LTD +2
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0018] Examining the current clinical medication situation, there is no effective and safe drug for comprehensively controlling dyslipidemia, so it is urgent to develop a blood lipid-lowering drug that can comprehensively reduce LDL-C, TG, and TC levels and increase HDL-C levels , to solve the deficiencies of existing clinical drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition containing fibrate drug and taurine
  • Composition containing fibrate drug and taurine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0038] Embodiment 1 prepares compound fenofibrate taurine sheet (1000 pieces amount)

[0039] Formula: Taurine 300g

[0040] Fenofibrate 200g

[0041] Lactose 160g

[0042] Microcrystalline Cellulose 50g

[0043] Sodium carboxymethyl starch 20g

[0044] Low-substituted hydroxypropyl cellulose 20g

[0045] Proper amount of povidone aqueous solution

[0046] Magnesium Stearate 1%

[0047] Preparation method: crush the raw and auxiliary materials through an 80-mesh sieve, and dry for later use. Take 300g of taurine and 200g of fenofibrate and mix uniformly according to the method of equal increase, add 160g of lactose, 50g of microcrystalline cellulose and 20g sodium carboxymethyl starch, mix uniformly according to the method of equal increase, and use 10% povidone The aqueous solution is made into a soft material, granulated with a 20-mesh sieve, dried at 60°C for about 2 hours, granulated with a 20-mesh sieve, and the water conte...

Embodiment 2

[0048] Embodiment 2 prepares compound bezafibrate taurine sheet (1000 pieces amount)

[0049] Formula: Taurine 100g

[0050] Bezafibrate 400g

[0051] Lactose 160g

[0052] Microcrystalline Cellulose 50g

[0053] Sodium carboxymethyl starch 20g

[0054] Low-substituted hydroxypropyl cellulose 20g

[0055] Proper amount of povidone aqueous solution

[0056] Magnesium Stearate 1%

[0057] The preparation method was the same as in Example 1, and each tablet contained 100 mg of taurine and 400 mg of bezafibrate in the prepared compound tablet, and the mass ratio was 1:4.

Embodiment 3

[0058] Embodiment 3 prepares compound gemfibrozil taurine sheet (1000 pieces amount)

[0059] Formula: Taurine 100g

[0060] Gemfibrozil 400g

[0061] Lactose 160g

[0062] Microcrystalline Cellulose 50g

[0063] Sodium carboxymethyl starch 30g

[0064] Low-substituted hydroxypropyl cellulose 20g

[0065]Proper amount of povidone aqueous solution

[0066] Magnesium Stearate 1%

[0067] The preparation method was the same as in Example 1, and each tablet contained 100 mg of taurine and 400 mg of gemfibrozil in the prepared compound tablet, and the mass ratio was 1:4.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a medicinal compound for improving blood lipid and body insulin resistance state. Said medicinal compound contains phenoxyaromatic acid medicine (including fenofibrate, bezafibrate and gemfibrozil, etc.) or its medicinal salt, taurine and medicinal carrier or excipient. Said medicinal compound also can be used for reducing total cholesterol (TC), low density lipoprotein (LDL) and triglyceride (TG) and raising high density lipoprotein (HDL), and can be used for curing abnormal blood-lipid and metabolic syndrome, etc.

Description

technical field [0001] The invention relates to a composition containing phenoxyaromatic acid drugs and taurine, and the application of the composition in preparing medicines for treating dyslipidemia or metabolic syndrome (metabolic syndrome, MS). The present invention belongs to the field of pharmacy. Background technique [0002] Dyslipidemia refers to blood total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), triglyceride (TG) exceeding the normal range and / or high-density lipoprotein cholesterol (HDL-C) below normal range. Dyslipidemia plays a very important role in the occurrence and development of atherosclerosis (AS) and the cardiovascular events (cardiovascular events, CVE) caused by it. one of the fastest growing fields. [0003] More and more research results show that dyslipidemia is one of the risk factors for coronary heart disease. The improvement of dyslipidemia can prevent or reverse the progression of atherosclerotic lesions, and can sig...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/192A61K31/185A61P3/06
Inventor 秦献辉于多王文艳王燕李华戴成祥陈光亮徐希平
Owner SHENZHEN AUSA PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products